Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites

Rhinoconjunctivitis With or Without Allergic Asthma Clinical Trial

Official title: Observational Prospective Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites

Status Completed

Clinical Trial Summary

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerised With House Dust Mite in pediatric allergic patients

Clinical Trial Description

This prospective open multi-center non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac polymerized with house dust mite pediatric allergic patients in routine medical care.

Patients receive a rush schedule administration every month for a year. They attend at least 5 study visits to inform about the adverse reactions, the self reported symptoms and the medication intake. ;

Related Conditions & MeSH terms

• Rhinoconjunctivitis With or Without Allergic Asthma

• NCT number: NCT03963947
• Study type: Observational
• Source: Centro Medico Teknon
• Status: Completed
• Start date: June 1, 2019
• Completion date: May 24, 2023